Market Research and Forecast of Antineoplastic Drugs in China 2016-2021
It takes 3-5 business days to dispatch the report after the purchase is made.
Antineoplastic drugs develop from traditional single antineoplastic drug towards a new type of antineoplastic drug aiming at functions at multiple links. Research and development of antineoplastic drugs have stepped in to a new stage.
Till now, there are nearly four million cases of new tumors in China every year. With aging of population, environmental pollution caused by industrialization and lifestyles changed by factors like urbanization, malignant tumors replace cardiovascular diseases and become the top killer in China, taking 25% in total deaths.
For the increasing incidence of tumors, released needs for antineoplastic drugs and improving technologies for the drugs, output of the drugs will further increase in China. According to statistics of ASKCI, in 2015, total output of antineoplastic drugs was about 440 tonnes, with the market scale of nearly RMB100 billion. Sales of transnational enterprise were more centered and generally focused on promotion of their key products. While domestic enterprises applied the strategy of sales in a wide range.
In 2021, the forecast of China antineoplastic drug market will reach more than RMB250 billion, relatively conservative compared to global market. Except adjuvant drugs like immunosuppressant, anti-metabolic will have the most market shares, with a stable growth. The second will be botanical preparations, remaining a relatively fast growth. Growth of alkylating agents, antibiotics and platinum drugs will tend to slow. As for targeted drugs, it is predicted that there is a large potential in independent R&D of targeted drugs, with the consideration of more supports by the government, and which will become the most important field leading domestic market of antineoplastic drugs.
Antineoplastic drugs develop from traditional single antineoplastic drug towards a new type of antineoplastic drug aiming at functions at multiple links. Research and development of antineoplastic drugs have stepped in to a new stage.
Till now, there are nearly four million cases of new tumors in China every year. With aging of population, environmental pollution caused by industrialization and lifestyles changed by factors like urbanization, malignant tumors replace cardiovascular diseases and become the top killer in China, taking 25% in total deaths.
For the increasing incidence of tumors, released needs for antineoplastic drugs and improving technologies for the drugs, output of the drugs will further increase in China. According to statistics of ASKCI, in 2015, total output of antineoplastic drugs was about 440 tonnes, with the market scale of nearly RMB100 billion. Sales of transnational enterprise were more centered and generally focused on promotion of their key products. While domestic enterprises applied the strategy of sales in a wide range.
In 2021, the forecast of China antineoplastic drug market will reach more than RMB250 billion, relatively conservative compared to global market. Except adjuvant drugs like immunosuppressant, anti-metabolic will have the most market shares, with a stable growth. The second will be botanical preparations, remaining a relatively fast growth. Growth of alkylating agents, antibiotics and platinum drugs will tend to slow. As for targeted drugs, it is predicted that there is a large potential in independent R&D of targeted drugs, with the consideration of more supports by the government, and which will become the most important field leading domestic market of antineoplastic drugs.
1 OVERVIEW OF CHINA ANTINEOPLASTIC DRUG INDUSTRY
1.1 Tumors in China
1.2 Supply and Demand
1.3 Competition Structure of China Antineoplastic Drug Industry
2 SALES CHANNELS OF ANTINEOPLASTIC DRUGS IN CHINA IN 2015
2.1 Hospitals
2.2 Drugstores
3 ANALYSIS OF MAJOR COMPANIES OF ANTINEOPLASTIC DRUGS IN CHINA
3.1 Jiangsu Hengrui Medicine Co., Ltd.
3.1.1 Development Analysis
3.1.2 Major Products
3.1.3 Operation Analysis
3.1.4 Competition Advantage
3.1.5 Sales Network
3.1.6 Development Strategy
3.2 China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC)
3.3 Guizhou Yibai Pharmaceutical Co., Ltd.
3.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
3.5 Beijing SL Pharmaceutical Co., Ltd.
3.6 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
4 ANALYSIS OF ANTINEOPLASTIC DRUGS BY SUBDIVISIONS
4.1 Paclitaxel
4.2 Docetaxel
4.3 Pemetrexed
4.4 Tegafur, Gimeracil and Oteracil Potassium
5 FORECAST OF ANTINEOPLASTIC DRUG INDUSTRY IN CHINA, 2016-2021
6 ANALYSIS OF INVESTMENT AND FINANCING STRATEGY PLAN OF ANTINEOPLASTIC DRUG INDUSTRY IN CHINA
6.1 Conclusion of Antineoplastic Drugs in China
6.2 Suggestions on Strategy Planning
6.2.1 Product Strategy
6.2.2 Channel Strategy
6.2.3 Development of Potential Market
6.2.4 Strategy of Market Competition
1.1 Tumors in China
1.2 Supply and Demand
1.3 Competition Structure of China Antineoplastic Drug Industry
2 SALES CHANNELS OF ANTINEOPLASTIC DRUGS IN CHINA IN 2015
2.1 Hospitals
2.2 Drugstores
3 ANALYSIS OF MAJOR COMPANIES OF ANTINEOPLASTIC DRUGS IN CHINA
3.1 Jiangsu Hengrui Medicine Co., Ltd.
3.1.1 Development Analysis
3.1.2 Major Products
3.1.3 Operation Analysis
3.1.4 Competition Advantage
3.1.5 Sales Network
3.1.6 Development Strategy
3.2 China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC)
3.3 Guizhou Yibai Pharmaceutical Co., Ltd.
3.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
3.5 Beijing SL Pharmaceutical Co., Ltd.
3.6 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
4 ANALYSIS OF ANTINEOPLASTIC DRUGS BY SUBDIVISIONS
4.1 Paclitaxel
4.2 Docetaxel
4.3 Pemetrexed
4.4 Tegafur, Gimeracil and Oteracil Potassium
5 FORECAST OF ANTINEOPLASTIC DRUG INDUSTRY IN CHINA, 2016-2021
6 ANALYSIS OF INVESTMENT AND FINANCING STRATEGY PLAN OF ANTINEOPLASTIC DRUG INDUSTRY IN CHINA
6.1 Conclusion of Antineoplastic Drugs in China
6.2 Suggestions on Strategy Planning
6.2.1 Product Strategy
6.2.2 Channel Strategy
6.2.3 Development of Potential Market
6.2.4 Strategy of Market Competition
LIST OF FIGURES
Figure 1 Output distribution of antineoplastic drugs by provinces in China
Figure 2 Market scales and growth rates of antineoplastic drugs in China, 2011-2015
Figure 3 Numbers of inpatients of cancer hospitals in China, 2011-2015
Figure 4 Business structure of Jiangsu Hengrui Medicine Co., Ltd. for the first half year in 2016
Figure 5 Business structure of China Shijiazhuang Pharmaceutical Group Co., Ltd. in 2016
Figure 6 Business structure of Guizhou Yibai Pharmaceutical Co., Ltd. in 2016
Figure 7 Business structure of Zhejiang HISUN Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Figure 8 Business structure of Beijing SL Pharmaceutical Co., Ltd. from Jan. to June in 2016
Figure 9 Market scale forecast of paclitaxel at sample hospitals in China, 2016-2021
Figure 10 Market scale forecast of docetaxel at sample hospitals in China, 2016-2021
Figure 11 Market scale forecast of pemetrexed at sample hospitals in China, 2016-2021
Figure 12 Market scale forecast of tegafur, gimeracil and oteracil potassium at sample hospitals in China, 2016-2021
Figure 13 Market scale forecast of antineoplastic drugs in China, 2016-2021
Figure 1 Output distribution of antineoplastic drugs by provinces in China
Figure 2 Market scales and growth rates of antineoplastic drugs in China, 2011-2015
Figure 3 Numbers of inpatients of cancer hospitals in China, 2011-2015
Figure 4 Business structure of Jiangsu Hengrui Medicine Co., Ltd. for the first half year in 2016
Figure 5 Business structure of China Shijiazhuang Pharmaceutical Group Co., Ltd. in 2016
Figure 6 Business structure of Guizhou Yibai Pharmaceutical Co., Ltd. in 2016
Figure 7 Business structure of Zhejiang HISUN Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Figure 8 Business structure of Beijing SL Pharmaceutical Co., Ltd. from Jan. to June in 2016
Figure 9 Market scale forecast of paclitaxel at sample hospitals in China, 2016-2021
Figure 10 Market scale forecast of docetaxel at sample hospitals in China, 2016-2021
Figure 11 Market scale forecast of pemetrexed at sample hospitals in China, 2016-2021
Figure 12 Market scale forecast of tegafur, gimeracil and oteracil potassium at sample hospitals in China, 2016-2021
Figure 13 Market scale forecast of antineoplastic drugs in China, 2016-2021
LIST OF TABLES
Table 1 Death rates of cancers and proportions in the death cause of China urban residents, 2011-2015
Table 2 Death rates of cancers and proportions in the death cause of China rural residents, 2011-2015
Table 3 Top ten cancers of most estimated cases in China in 2015
Table 4 Top ten cancers of most estimated deaths in China in 2015
Table 5 Deaths and cases by age groups in China in 2015
Table 6 Outputs of major antineoplastic drug producers in China
Table 7 Outputs of antineoplastic drugs in China, 2011-2015
Table 8 Top ten antineoplastic drugs of the largest purchase amount in China in 2015
Table 9 Antineoplastic drug companies of the largest purchase amount by regions in China in 2015
Table 10 Numbers of hospitals and cancer hospitals in China, 2011-2015
Table 11 Numbers of beds in oncology department of medical and health institutions in China, 2011-2015
Table 12 Numbers of patients of oncology department in hospitals in China, 2011-2015
Table 13 Numbers of patients of cancer hospitals in China, 2011-2015
Table 14 Numbers of discharged patients in oncology department of hospitals in China, 2011-2015
Table 15 Numbers of discharged patients of cancer hospitals in China, 2011-2015
Table 16 Average annual medical expenditures per peasant of six cancers in China, 2013-2015
Table 17 Numbers of drugstores in China, 2011-2015
Table 18 Antineoplastic drugs of Jiangsu Hengrui Medicine Co., Ltd.
Table 19 Outputs and sales of Jiangsu Hengrui Medicine Co., Ltd. in 2015
Table 20 Operation of Jiangsu Hengrui Medicine Co., Ltd. by industries and products for the first half year in 2016
Table 21 Revenues and profits of Jiangsu Hengrui Medicine Co., Ltd., 2012-2016
Table 22 Competition advantages of Jiangsu Hengrui Medicine Co., Ltd.
Table 23 Revenues of Jiangsu Hengrui Medicine Co., Ltd. by regions for the first half year in 2016
Table 24 Antineoplastic drugs of China Shijiazhuang Pharmaceutical Group Co., Ltd.
Table 25 Revenues of China Shijiazhuang Pharmaceutical Group Co., Ltd. by products, 2015-2016
Table 26 Revenues and profits of China Shijiazhuang Pharmaceutical Group Co., Ltd., 2012-2016
Table 27 Competition advantages of China Shijiazhuang Pharmaceutical Group Co., Ltd.
Table 28 Antineoplastic drugs of Guizhou Yibai Pharmaceutical Co., Ltd.
Table 29 Sales and outputs of antineoplastic drugs of Guizhou Yibai Pharmaceutical Co., Ltd. in 2015
Table 30 Revenues of Guizhou Yibai Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 31 Revenues and profits of Guizhou Yibai Pharmaceutical Co., Ltd., 2012-2016
Table 32 Revenues of Guizhou Yibai Pharmaceutical Co., Ltd. by regions for the first half year in 2016
Table 33 Competition advantages of Guizhou Yibai Pharmaceutical Co., Ltd.
Table 34 Businesses of Zhejiang HISUN Pharmaceutical Co., Ltd.
Table 35 Sales and outputs of Zhejiang HISUN Pharmaceutical Co., Ltd. in 2015
Table 36 Revenues of Zhejiang HISUN Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 37 Revenues and profits of Zhejiang HISUN Pharmaceutical Co., Ltd., 2012-2016
Table 38 Revenues of Zhejiang HISUN Pharmaceutical Co., Ltd. by regions from Jan. to June in 2016
Table 39 Competition advantages of Zhejiang HISUN Pharmaceutical Co., Ltd.
Table 40 Antineoplastic drugs of Beijing SL Pharmaceutical Co., Ltd.
Table 41 Outputs and sales of products of Beijing SL Pharmaceutical Co., Ltd., 2014-2015
Table 42 Revenues of Beijing SL Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 43 Revenues and profits of Beijing SL Pharmaceutical Co., Ltd., 2012-2016
Table 44 Revenues of Beijing SL Pharmaceutical Co., Ltd. by regions from Jan. to June in 2016
Table 45 Competition advantages of Beijing SL Pharmaceutical Co., Ltd.
Table 46 Development strategy of Beijing SL Pharmaceutical Co., Ltd.
Table 47 Antineoplastic drugs of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 48 Revenues and profits of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2011-2014
Table 49 Sales profit rates and gross profit rates of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2011-2014
Table 50 Competition advantages of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 51 Sales values and market shares of paclitaxel at sample hospitals in China, 2011-2015
Table 52 Paclitaxel manufacturers in China
Table 53 Sales values and market shares of docetaxel at sample hospitals in China, 2011-2015
Table 54 Docetaxel manufacturers in China
Table 55 Sales values and market shares of pemetrexed at sample hospitals in China, 2011-2015
Table 56 Pemetrexed manufacturers in China
Table 57 Sales values and market shares of tegafur, gimeracil and oteracil potassium at sample hospitals in China, 2011-2015
Table 58 Tegafur, gimeracil and oteracil potassium manufacturers in China
Table 59 Strategy of market competition in China antineoplastic drug industry
Table 1 Death rates of cancers and proportions in the death cause of China urban residents, 2011-2015
Table 2 Death rates of cancers and proportions in the death cause of China rural residents, 2011-2015
Table 3 Top ten cancers of most estimated cases in China in 2015
Table 4 Top ten cancers of most estimated deaths in China in 2015
Table 5 Deaths and cases by age groups in China in 2015
Table 6 Outputs of major antineoplastic drug producers in China
Table 7 Outputs of antineoplastic drugs in China, 2011-2015
Table 8 Top ten antineoplastic drugs of the largest purchase amount in China in 2015
Table 9 Antineoplastic drug companies of the largest purchase amount by regions in China in 2015
Table 10 Numbers of hospitals and cancer hospitals in China, 2011-2015
Table 11 Numbers of beds in oncology department of medical and health institutions in China, 2011-2015
Table 12 Numbers of patients of oncology department in hospitals in China, 2011-2015
Table 13 Numbers of patients of cancer hospitals in China, 2011-2015
Table 14 Numbers of discharged patients in oncology department of hospitals in China, 2011-2015
Table 15 Numbers of discharged patients of cancer hospitals in China, 2011-2015
Table 16 Average annual medical expenditures per peasant of six cancers in China, 2013-2015
Table 17 Numbers of drugstores in China, 2011-2015
Table 18 Antineoplastic drugs of Jiangsu Hengrui Medicine Co., Ltd.
Table 19 Outputs and sales of Jiangsu Hengrui Medicine Co., Ltd. in 2015
Table 20 Operation of Jiangsu Hengrui Medicine Co., Ltd. by industries and products for the first half year in 2016
Table 21 Revenues and profits of Jiangsu Hengrui Medicine Co., Ltd., 2012-2016
Table 22 Competition advantages of Jiangsu Hengrui Medicine Co., Ltd.
Table 23 Revenues of Jiangsu Hengrui Medicine Co., Ltd. by regions for the first half year in 2016
Table 24 Antineoplastic drugs of China Shijiazhuang Pharmaceutical Group Co., Ltd.
Table 25 Revenues of China Shijiazhuang Pharmaceutical Group Co., Ltd. by products, 2015-2016
Table 26 Revenues and profits of China Shijiazhuang Pharmaceutical Group Co., Ltd., 2012-2016
Table 27 Competition advantages of China Shijiazhuang Pharmaceutical Group Co., Ltd.
Table 28 Antineoplastic drugs of Guizhou Yibai Pharmaceutical Co., Ltd.
Table 29 Sales and outputs of antineoplastic drugs of Guizhou Yibai Pharmaceutical Co., Ltd. in 2015
Table 30 Revenues of Guizhou Yibai Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 31 Revenues and profits of Guizhou Yibai Pharmaceutical Co., Ltd., 2012-2016
Table 32 Revenues of Guizhou Yibai Pharmaceutical Co., Ltd. by regions for the first half year in 2016
Table 33 Competition advantages of Guizhou Yibai Pharmaceutical Co., Ltd.
Table 34 Businesses of Zhejiang HISUN Pharmaceutical Co., Ltd.
Table 35 Sales and outputs of Zhejiang HISUN Pharmaceutical Co., Ltd. in 2015
Table 36 Revenues of Zhejiang HISUN Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 37 Revenues and profits of Zhejiang HISUN Pharmaceutical Co., Ltd., 2012-2016
Table 38 Revenues of Zhejiang HISUN Pharmaceutical Co., Ltd. by regions from Jan. to June in 2016
Table 39 Competition advantages of Zhejiang HISUN Pharmaceutical Co., Ltd.
Table 40 Antineoplastic drugs of Beijing SL Pharmaceutical Co., Ltd.
Table 41 Outputs and sales of products of Beijing SL Pharmaceutical Co., Ltd., 2014-2015
Table 42 Revenues of Beijing SL Pharmaceutical Co., Ltd. by industries and products from Jan. to June in 2016
Table 43 Revenues and profits of Beijing SL Pharmaceutical Co., Ltd., 2012-2016
Table 44 Revenues of Beijing SL Pharmaceutical Co., Ltd. by regions from Jan. to June in 2016
Table 45 Competition advantages of Beijing SL Pharmaceutical Co., Ltd.
Table 46 Development strategy of Beijing SL Pharmaceutical Co., Ltd.
Table 47 Antineoplastic drugs of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 48 Revenues and profits of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2011-2014
Table 49 Sales profit rates and gross profit rates of Jiangsu Aosaikang Pharmaceutical Co., Ltd., 2011-2014
Table 50 Competition advantages of Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Table 51 Sales values and market shares of paclitaxel at sample hospitals in China, 2011-2015
Table 52 Paclitaxel manufacturers in China
Table 53 Sales values and market shares of docetaxel at sample hospitals in China, 2011-2015
Table 54 Docetaxel manufacturers in China
Table 55 Sales values and market shares of pemetrexed at sample hospitals in China, 2011-2015
Table 56 Pemetrexed manufacturers in China
Table 57 Sales values and market shares of tegafur, gimeracil and oteracil potassium at sample hospitals in China, 2011-2015
Table 58 Tegafur, gimeracil and oteracil potassium manufacturers in China
Table 59 Strategy of market competition in China antineoplastic drug industry
